ClinicalTrials.Veeva

Menu

Using Conversation Maps to Reinforce Self-Care

Joslin Diabetes Center logo

Joslin Diabetes Center

Status

Completed

Conditions

Type 2 Diabetes

Treatments

Behavioral: Heart Healthy Living Diabetes Education
Behavioral: Conversation Maps Diabetes Education

Study type

Interventional

Funder types

Other

Identifiers

NCT00895986
ADA 7-08-CR-62
CHS #08-07

Details and patient eligibility

About

Many people with type 2 diabetes are not able to keep their blood glucose in good control. Improving blood glucose control and maintaining that improvement is important for diabetes patients because doing so delays the onset and progression of severe complications of diabetes. Although educational programs may be helpful, their effect is not always long-lasting. This project is studying whether the Conversation Maps program (an interactive diabetes education program) reinforces diabetes education and information and thus helps type 2 diabetes patients take better care of their diabetes and blood glucose levels. Half of the patients will attend the Conversation Maps program and half of the patients will attend an educational program about blood pressure and cholesterol. Also, all patients will come in for 4 or 5 appointments to complete surveys and other tests and have their blood drawn. The group of patients who attend the Conversation Maps program will be compared to the group of patients who attend the blood pressure and cholesterol program to see if the educational programs helped diabetes patients to improve their diabetes control and quality of life and to maintain that improvement over time.

Enrollment

134 patients

Sex

All

Ages

25 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Ages 25-75 years
  • Diagnosis of type 2 diabetes mellitus
  • Two A1c levels ≥7.0 % (above ADA target)
  • 2 years since initial diagnosis. This will provide a minimum of two-years experience with diabetes treatment. Also, excluding those who are newly diagnosed will prevent improvement due to newly prescribed medications from confounding study results.
  • Attended one of Joslin's group education programs or comparable 3-hour (or more) educational programs and/or appointments

Exclusion criteria

  • Severe complications of diabetes including renal disease (microalbumin >300 ug/mg), severe peripheral diabetic neuropathy and/or severe peripheral vascular disease, symptomatic severe autonomic neuropathy, that may place participants at risk when increasing activity levels.
  • Proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included.
  • Current or planned pregnancy
  • A1c levels less than 7.0% (normal range 4.0 - 6.0%) and A1c levels greater than 14%.
  • A history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, or severe hypertension (systolic ≥160 mmHg or diastolic ≥ 90 mmHg) (increased risk when mildly increasing physical activity).
  • A diagnosis of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse will be excluded, as well as patients currently undergoing psychiatric treatment. These exclusions are being made to avoid confounds due to concurrent changes in mental status and the effects of ongoing psychiatric treatment.
  • Used Conversation Maps as an educational tool
  • Started a new diabetes medication (pills or insulin) in past three months

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

134 participants in 2 patient groups

1
Experimental group
Description:
Conversation Maps Diabetes Education
Treatment:
Behavioral: Conversation Maps Diabetes Education
2
Experimental group
Description:
Heart Healthy Living Diabetes Education
Treatment:
Behavioral: Heart Healthy Living Diabetes Education

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems